Talk:Casirivimab/imdevimab

Costs?

These things are usually very expensive to produce. Does anyone here know what Regeneron are charging per dose? — Preceding unsigned comment added by 2001:8003:E414:3A01:193F:3E1C:6B49:6166 (talk) 01:15, 3 October 2020 (UTC)

p=0.22 and p=0.09

Patients who were seronegative and/or had higher baseline viral levels also had greater benefits in terms of symptom alleviation. Among seronegative patients, median time to symptom alleviation (defined as symptoms becoming mild or absent) was 13 days in placebo, 8 days in high dose (p=0.22), and 6 days in low dose (p=0.09).

If the p-value is less than or equal to the alpha (p≤.05), then we reject the null hypothesis, and we say the result is statistically significant. If the p-value is greater than alpha (p > .05), then we fail to reject the null hypothesis, and we say that the result is statistically nonsignificant (n.s.).

How can this be an effective treatment when there is nothing statistically significant about it improving the time to symptom alleviation?

Jamplevia (talk) 17:37, 4 October 2020 (UTC)

Science magazine story

Good story in Science. Main point is that for 1/3 of the patients who didn't produce antibodies, mortality was reduced from 30% to 24%.

https://www.sciencemag.org/news/2021/06/monoclonal-antibodies-cut-risk-dying-covid-19-only-some-patients
Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients
By Kai Kupferschmidt
Jun. 16, 2021

About one-third of the patients were seronegative when they entered the trial, meaning they did not produce antibodies themselves. That includes people with underlying health conditions that weaken their immune system, but also people who, for unclear reasons, are unable to produce antibodies early on. In this group, 30% of patients given standard care died, versus 24% of those who received the antibody cocktail. That translates to six lives saved for every 100 such patients treated with the drug.

https://www.recoverytrial.net/results/monoclonal-antibody-combination-results
Recovery Trial
Regeneron's monoclonal antibody combination results
PRESS RELEASE
16 June 2021

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

Nbauman (talk) 04:14, 16 August 2021 (UTC)

Mechanism of Action?

I feel like this article is sorely missing a "Mechanism of Action" section, especially given the fact that REGEN-COV is, to my knowledge, the first mAb treatment (or was that Palivizumab?) that's been commercialized as an antiviral. NixonFan1962 (talk) 18:26, 17 September 2021 (UTC)